Every year, on September 29, the World Heart Federation asks people around the world to join together on World Heart Day and bring awareness to the global impact of cardiovascular disease (CVD) – the leading cause of death worldwide. This year, the #UseHeart campaign is focusing on three pillars: equity, prevention and community.
While each of these pillars is integral in driving awareness of the importance of global cardiovascular health, the CSL Behring Cardiovascular and Metabolic (CV&M) team has a particular focus on prevention as it is a core part of our goals to help improve the outlook of people who have survived a heart attack.
“Despite decades of progress in lowering the overall rate of heart attack with new treatment modalities, the risk of having another coronary event remains high,” said Dr. Larry Deckelbaum, Vice President, Research and Development, Cardiovascular and Metabolic Therapeutic Area at CSL Behring. “Our company is continually driven by a promise to put patients first. We are proud to be a part of the #UseHeart movement to reduce the burden of cardiovascular disease through our ongoing Phase 3 research.”
To learn more about World Heart Day and the #UseHeart campaign, visit the World Heart Federation website.
To find out more about CSL Behring’s latest efforts in cardiovascular research, check out a recent article by Dr. Deckelbaum.